CA2819642C - Histone inhibition - Google Patents

Histone inhibition Download PDF

Info

Publication number
CA2819642C
CA2819642C CA2819642A CA2819642A CA2819642C CA 2819642 C CA2819642 C CA 2819642C CA 2819642 A CA2819642 A CA 2819642A CA 2819642 A CA2819642 A CA 2819642A CA 2819642 C CA2819642 C CA 2819642C
Authority
CA
Canada
Prior art keywords
group
histone
sulfate
monosaccharide
polyanion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2819642A
Other languages
English (en)
French (fr)
Other versions
CA2819642A1 (en
Inventor
Ross Wentworth Stephens
Christopher Richard Parish
Craig Geoffrey Freeman
Timothy John Senden
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Australian National University
Original Assignee
Australian National University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Australian National University filed Critical Australian National University
Publication of CA2819642A1 publication Critical patent/CA2819642A1/en
Application granted granted Critical
Publication of CA2819642C publication Critical patent/CA2819642C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
CA2819642A 2010-12-01 2011-11-29 Histone inhibition Active CA2819642C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41882610P 2010-12-01 2010-12-01
US61/418,826 2010-12-01
PCT/AU2011/001550 WO2012071611A1 (en) 2010-12-01 2011-11-29 Histone inhibition

Publications (2)

Publication Number Publication Date
CA2819642A1 CA2819642A1 (en) 2012-06-07
CA2819642C true CA2819642C (en) 2019-07-16

Family

ID=46171086

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2819642A Active CA2819642C (en) 2010-12-01 2011-11-29 Histone inhibition

Country Status (15)

Country Link
US (1) US9226939B2 (https=)
EP (1) EP2646037B1 (https=)
JP (2) JP2014501730A (https=)
KR (1) KR101956335B1 (https=)
CN (1) CN103402526B (https=)
AU (1) AU2011335881B2 (https=)
BR (1) BR112013013544B1 (https=)
CA (1) CA2819642C (https=)
DK (1) DK2646037T3 (https=)
ES (1) ES2710857T3 (https=)
HU (1) HUE043546T2 (https=)
IL (1) IL226667A (https=)
NZ (1) NZ611316A (https=)
SG (1) SG190438A1 (https=)
WO (1) WO2012071611A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3105593B2 (ja) 1991-10-18 2000-11-06 東海パルプ株式会社 パルパー制御装置
CN110446511B (zh) 2017-03-10 2024-04-02 北卡罗来纳大学查珀尔希尔分校 短效的基于肝素的抗凝血剂化合物和方法
WO2019010216A1 (en) 2017-07-03 2019-01-10 The University Of North Carolina At Chapel Hill ENZYMATIC SYNTHESIS OF HOMOGENEOUS CHONDROITIN SULFATE OLIGOSACCHARIDES
JP7495061B2 (ja) 2017-11-03 2024-06-04 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 抗炎症作用を有する硫酸化オリゴ糖
CN111479574B (zh) * 2017-12-15 2024-02-09 澳大利亚国立大学 用于治疗和预防细胞外组蛋白介导的病理的化合物
CN112437667B (zh) * 2018-06-20 2024-05-28 北卡罗来纳大学查珀尔希尔分校 细胞保护方法和组合物
WO2020033824A1 (en) * 2018-08-09 2020-02-13 University Of Vermont And State Agricultural College Inhibitors of acute severe inflammatory conditions
WO2020172698A1 (en) * 2019-02-25 2020-09-03 The Australian National University Compounds for treating and preventing net associated complications
WO2021097345A1 (en) 2019-11-13 2021-05-20 The University Of North Carolina At Chapel Hill Heparan sulfate (hs) oligosaccharides effect in liver ischemia reperfusion injury
WO2022116981A1 (zh) * 2020-12-01 2022-06-09 远大医药（中国）有限公司 一种聚阴离子纤维二糖苷类化合物的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4847338A (en) 1985-03-28 1989-07-11 University Of Iowa Research Foundation Low molecular weight heparin fragments as inhibitors of complement activation
DK505488D0 (da) * 1987-12-21 1988-09-09 Bar Shalom Daniel Middel og anvendelse af samme
US5583121A (en) * 1994-01-12 1996-12-10 Michigan State University Non-anticoagulant chemically modified heparinoids for treating hypovolemic shock and related shock syndromes
CA2158715C (en) 1994-09-21 2005-11-08 Rodney Browitt A precipitator
AUPN261895A0 (en) * 1995-04-28 1995-05-18 Australian National University, The Preparation and use of sulfated oligosaccharides
WO1999004826A1 (en) 1997-07-24 1999-02-04 The Australian National University Method for detection of fibrin clots
ITMI20021294A1 (it) * 2002-06-12 2003-12-12 Inalco Spa Polisaccaridi batterici o-solfatati e loro uso
US20050282775A1 (en) 2004-06-16 2005-12-22 Paringenix, Inc. Method and medicament for sulfated polysaccharide treatment of inflammation without inducing platelet activation and heparin-induced thrombocytopenia syndrome
US7468358B2 (en) * 2004-06-16 2008-12-23 Paringenix, Inc. Method and medicament for sulfated polysaccharide treatment of heparin-induced thrombocytopenia (HIT) syndrome
WO2006015171A2 (en) * 2004-07-28 2006-02-09 The Texas A & M University System Use of glycosoaminoglycans for the prevention and treatment of sepsis
NZ562855A (en) 2005-04-29 2010-01-29 Univ Australian A method of forming an injectable radioactive composition of a carbon encapsulated radioactive particulate
EP1747785A1 (en) * 2005-07-28 2007-01-31 Istituto Clinico Humanitas Cyclodextrins for blood detoxification
AU2006318216C1 (en) * 2005-11-28 2012-02-16 Verrow Pharmaceuticals, Inc. Compositions useful for reducing nephrotoxicity and methods of use thereof
WO2007095688A1 (en) 2006-02-23 2007-08-30 The Australian National University Methods for increasing the number of circulating cells
GB2450087A (en) * 2007-06-11 2008-12-17 Diosamine Dev Corp Use of sulphated saccharides in the treatment of inflammatory and/or auto-immune diseases
EP2209485B1 (en) * 2007-11-06 2016-03-30 Oklahoma Medical Research Foundation Extracellular histones as biomarkers for prognosis and molecular targets for therapy
CA2721836C (en) 2008-04-24 2017-04-11 The Australian National University Methods for radiolabelling macromolecules
JP2011256111A (ja) * 2008-10-03 2011-12-22 Hayashibara Biochem Lab Inc 敗血症の予防及び治療剤

Also Published As

Publication number Publication date
KR101956335B1 (ko) 2019-03-08
DK2646037T3 (en) 2019-03-04
US9226939B2 (en) 2016-01-05
AU2011335881A1 (en) 2013-06-20
US20130338097A1 (en) 2013-12-19
KR20130121877A (ko) 2013-11-06
CA2819642A1 (en) 2012-06-07
NZ611316A (en) 2014-12-24
ES2710857T3 (es) 2019-04-29
HUE043546T2 (hu) 2019-08-28
EP2646037A1 (en) 2013-10-09
JP2016193917A (ja) 2016-11-17
EP2646037B1 (en) 2019-01-09
WO2012071611A1 (en) 2012-06-07
SG190438A1 (en) 2013-07-31
CN103402526B (zh) 2016-01-20
JP6142039B2 (ja) 2017-06-07
BR112013013544B1 (pt) 2020-09-29
CN103402526A (zh) 2013-11-20
EP2646037A4 (en) 2015-03-18
IL226667A (en) 2017-02-28
JP2014501730A (ja) 2014-01-23
BR112013013544A2 (pt) 2016-10-11
AU2011335881B2 (en) 2016-07-14

Similar Documents

Publication Publication Date Title
CA2819642C (en) Histone inhibition
Bachelet et al. Affinity of low molecular weight fucoidan for P-selectin triggers its binding to activated human platelets
Laurent et al. The properties and turnover of hyaluronan
US6391857B1 (en) Methods and compositions for endothelial binding
EP2416806B1 (en) Fucoidans as ligands for the diagnosis of degenerative pathologies
US20080112955A1 (en) Method and composition for preventing pain in sickle cell patients
US5902795A (en) Oligosaccharides reactive with hyaluronan-binding protein and their methods of use
JPS62502260A (ja) 抗ウイルス剤
JPH01503548A (ja) ヘパリン誘導体
JP2016527252A5 (https=)
HUP9903538A2 (hu) Oligoszacharidok alkalmazása szövetmembrán-elégtelenség kezelésére szolgáló gyógyászati készítmények előállítására
US9572831B2 (en) Composition and method for sulfated non-anticoagulant low molecular weight heparins in cancer and tumor metastasis
US10781235B2 (en) Multivalent ligand-lipid constructs
Alban et al. PS3, a semisynthetic β-1, 3-glucan sulfate, diminishes contact hypersensitivity responses through inhibition of L-and P-selectin functions
JP5508421B2 (ja) 薬剤として有用なポリ硫酸カルボキシエチル化シクロデキストリン
HK1188125A (en) Use of polyanions to inhibit the cytotoxic activity of histones in the treatment of sepsis
HK1188125B (en) Use of polyanions to inhibit the cytotoxic activity of histones in the treatment of sepsis
JP2004059506A (ja) セレクチン及びケモカインに作用する過硫酸化オリゴ糖
PT1917018E (pt) Sulfato de inulina para o tratamento de osteoartrite
JP6395880B2 (ja) 変性病変の診断のためのリガンドとしてのフコイダン
JP6099055B2 (ja) 変性病変の診断のためのリガンドとしてのフコイダン

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20161118

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD

Year of fee payment: 13

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241107

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241107

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241107

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 14TH ANNIV.) - STANDARD

Year of fee payment: 14

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251007

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251007